SK154796A3 - Use of rapamycin for the inhibition of neuronal cells necrosis - Google Patents

Use of rapamycin for the inhibition of neuronal cells necrosis Download PDF

Info

Publication number
SK154796A3
SK154796A3 SK1547-96A SK154796A SK154796A3 SK 154796 A3 SK154796 A3 SK 154796A3 SK 154796 A SK154796 A SK 154796A SK 154796 A3 SK154796 A3 SK 154796A3
Authority
SK
Slovakia
Prior art keywords
rapamycin
nmda
compound
adduct
diels
Prior art date
Application number
SK1547-96A
Other languages
English (en)
Slovak (sk)
Inventor
Stephen Shi-Hsun Lin
Katherine Lu Molnar-Kimber
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of SK154796A3 publication Critical patent/SK154796A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1547-96A 1995-12-07 1996-12-04 Use of rapamycin for the inhibition of neuronal cells necrosis SK154796A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US833795P 1995-12-07 1995-12-07

Publications (1)

Publication Number Publication Date
SK154796A3 true SK154796A3 (en) 1997-09-10

Family

ID=21731060

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1547-96A SK154796A3 (en) 1995-12-07 1996-12-04 Use of rapamycin for the inhibition of neuronal cells necrosis

Country Status (23)

Country Link
EP (1) EP0778023B1 (fr)
JP (1) JPH09183727A (fr)
KR (1) KR970032856A (fr)
CN (1) CN1112925C (fr)
AR (1) AR008747A1 (fr)
AT (1) ATE234095T1 (fr)
AU (1) AU700653B2 (fr)
BR (1) BR9605895A (fr)
CA (1) CA2192298A1 (fr)
CZ (2) CZ6498A3 (fr)
DE (1) DE69626610T2 (fr)
DK (1) DK0778023T3 (fr)
ES (1) ES2188730T3 (fr)
HU (1) HUP9603370A3 (fr)
IL (1) IL119778A (fr)
MX (1) MX9606131A (fr)
NO (1) NO309966B1 (fr)
NZ (1) NZ299888A (fr)
PT (1) PT778023E (fr)
SI (1) SI0778023T1 (fr)
SK (1) SK154796A3 (fr)
TW (1) TW427904B (fr)
ZA (1) ZA9610245B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002535A1 (fr) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou Nouvelle utilisation des antagonistes du glutamate pour le traitement du cancer
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2001079177A1 (fr) * 2000-04-17 2001-10-25 Gpi Nil Holdings, Inc. Composes diaza cycliques pour le traitement de troubles neurodegeneratifs
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
EP1622625A1 (fr) * 2003-04-09 2006-02-08 Wyeth Compositions pharmaceutiques pour administration intranasale d'acide phosphonique [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o]non-1 (7)-en-2-yl)alkyle] et derives et leurs procedes d'utilisation
CN1863810B (zh) 2003-04-09 2010-12-01 惠氏公司 [2-(8，9-二氧代-2，6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用
WO2004089369A2 (fr) * 2003-04-11 2004-10-21 Cambridge University Technical Services Limited Methodes et moyens permettant de traiter des troubles de conformation des proteines
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
GT200400213A (es) 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
RU2007119585A (ru) 2004-12-20 2009-01-27 Вайет (Us) Производные рапамицина и их применение при лечении неврологических заболеваний
WO2006068932A2 (fr) * 2004-12-20 2006-06-29 Wyeth Analogues de rapamycine et leurs utilisations dans le traitement de troubles neurologiques, proliferatifs, et inflammatoires
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (fr) 2007-11-30 2009-06-03 Pharnext Nouvelles approches thérapeutiques pour traiter la maladie de Charcot-Marie-Tooth
EP2135607A1 (fr) 2008-06-18 2009-12-23 Pharnext Combinaison de pilocarpine et methimazol pour le traitement de la maladie de Charcot-MarieTooth et des troubles associés
AU2010233073B2 (en) * 2009-04-10 2014-07-31 Haiyan Qi Novel anti-aging agents and methods to identify them
EP2263665A1 (fr) 2009-06-02 2010-12-22 Pharnext Nouvelles compositions pour traiter le CMT et troubles associés
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
US20120122913A1 (en) * 2009-07-24 2012-05-17 Institut National De La Recherche Scientifque Combination of curcuminoids and mtor inhibitors for the treatment of tauopathies
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9121859B2 (en) * 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
LT3003268T (lt) 2013-06-05 2018-12-10 Pharnext Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api)
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US20200354445A1 (en) * 2017-11-15 2020-11-12 Vanderbilt University Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease
CN114366738A (zh) * 2021-12-20 2022-04-19 中国人民解放军军事科学院军事医学研究院 雷帕霉素在促进神经干细胞扩增中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5260299A (en) * 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
MX9606131A (es) 1997-08-30
AU700653B2 (en) 1999-01-14
SI0778023T1 (en) 2003-08-31
CZ6498A3 (cs) 1998-06-17
DE69626610T2 (de) 2003-10-02
AU7417896A (en) 1997-06-12
DE69626610D1 (de) 2003-04-17
IL119778A (en) 1999-07-14
EP0778023A1 (fr) 1997-06-11
IL119778A0 (en) 1997-03-18
HU9603370D0 (en) 1997-01-28
ZA9610245B (en) 1998-06-05
CA2192298A1 (fr) 1997-06-08
NO965238L (no) 1997-06-09
NZ299888A (en) 2001-02-23
CZ354496A3 (cs) 1998-03-18
EP0778023B1 (fr) 2003-03-12
NO309966B1 (no) 2001-04-30
PT778023E (pt) 2003-06-30
ES2188730T3 (es) 2003-07-01
HUP9603370A2 (en) 1997-05-28
HUP9603370A3 (en) 1998-12-28
ATE234095T1 (de) 2003-03-15
KR970032856A (ko) 1997-07-22
AR008747A1 (es) 2000-02-23
CN1112925C (zh) 2003-07-02
CN1159915A (zh) 1997-09-24
TW427904B (en) 2001-04-01
JPH09183727A (ja) 1997-07-15
DK0778023T3 (da) 2003-06-30
NO965238D0 (no) 1996-12-06
BR9605895A (pt) 1998-08-18

Similar Documents

Publication Publication Date Title
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
MXPA96006131A (en) Neuroprotect agents
Beal et al. Systemic approaches to modifying quinolinic acid striatal lesions in rats
JP2003535034A (ja) ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
EP0485431B1 (fr) Agonistes partiels du site modulateur de glycine insensible a la strychnine du complexe recepteur de n-methyle-d-aspartate comme agents neuropsychopharmacologiques
JP2017534673A (ja) 精神病性障害を治療するための方法および組成物
AU2011285611B2 (en) Inhibitors of ERK for developmental disorders of neuronal connectivity
WO1999051223A1 (fr) Ansamycines benzoquinoides pour le traitement d'une crise ou d'un arret cardiaque
EP3746057B1 (fr) Dapansutrile pour la prévention ou le traitement de la maladie d'alzheimer
Schorderet Alzheimer's disease: fundamental and therapeutic aspects
DE69824165T2 (de) Verwendung von chelerythrin und strahlung in der tumortherapie
US20080207697A1 (en) Use of Epothilones in the Treatment of Neuronal Connectivity Defects Such as Schizophrenia and Autism
EP2874617B1 (fr) Baclofène et acamprosate utilisés en thérapie de maladie de dégénérescence maculaire
US20230390223A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
IL302223A (en) Intranasal administration of suramin for the treatment of nervous system disorders
EP2421532A2 (fr) Dérivés de spipérone et méthodes de traitement de troubles
WO2004096222A1 (fr) Utilisation de 1-(5-isoquinolinesulfonyl)homopiperazine, de ses metabolites actifs, de ses isomeres et de ses sels pour traiter et prevenir l'hypopigmentation
US20080287405A1 (en) Compositions and Methods Relating to Protein Kinase Inhibitors
JP2015500805A (ja) 認知強化方法
EP1471901B1 (fr) Derive de spermidine destine au traitement de maladies neurodegeneratives chroniques
EP1408944B1 (fr) Composes derives de l'erucamide destines au traitement et a la prevention des desordres du systeme secreteur
US6608080B1 (en) Morphan derivatives or salts thereof and medicinal compositions containing the same
EP1993612A2 (fr) Compositions et procédés de traitement de troubles cognitifs
WO2015027040A2 (fr) Méthodes et compositions pour le traitement d'une infection à schistosomes